This has been a big week in the long-running — and still very much not-over — saga of the Jeffrey Epstein files.
Q4 2025 earnings call highlights: 2026 revenue outlook, ALYFTREK progress, CASGEVY/JOURNAVX growth, and renal pipeline—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results